Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi.
Streptococcus pneumoniae infections can be prevented by using new conjugate vaccines, but these vaccines have limited serogroup coverage. We report the first serogrouping data from carried and invasive isolates obtained from children and adults in Malawi. The 7-valent vaccine would cover 41% of invasive isolates from children and 25% from adults. A 9-valent vaccine, including types 1 and 5, would cover 66% of invasive isolates from children and 55% from adults.
Gordon
Stephen B
SB
Wellcome Trust Research Laboratories, University of Malawi, Liverpool, UK. sgordon@mlw.medcol.mw
Kanyanda
Stonard
S
Walsh
Amanda L
AL
Goddard
Kirsty
K
Chaponda
Mas
M
Atkinson
Victoria
V
Mulwafu
Wakisa
W
Molyneux
Elizabeth M
EM
Zijlstra
Ed E
EE
Molyneux
Malcolm E
ME
Graham
Steve M
SM
D000328:Adult; D002353:Carrier State; D002648:Child; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D008295:Malawi / Q000453:epidemiology; D022401:Meningococcal Vaccines / Q000276:immunology / Q000627:therapeutic use; D009305:Nasopharynx / Q000382:microbiology; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology / Q000627:therapeutic use; D011159:Population Surveillance; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000276:immunology / Q000302:isolation & purification
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines